These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 11420084)

  • 21. The selective cannabinoid antagonist SR 141716A blocks cannabinoid-induced antinociception in rats.
    Lichtman AH; Martin BR
    Pharmacol Biochem Behav; 1997; 57(1-2):7-12. PubMed ID: 9164547
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anxiety does not affect the antinociceptive effect of Delta 9-THC in mice: participation of cannabinoid and opioid receptors.
    Takahashi RN; Ramos GA; Assini FL
    Pharmacol Biochem Behav; 2003 Jul; 75(4):763-8. PubMed ID: 12957217
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Inhibitors of endocannabinoid-metabolizing enzymes reduce precipitated withdrawal responses in THC-dependent mice.
    Schlosburg JE; Carlson BL; Ramesh D; Abdullah RA; Long JZ; Cravatt BF; Lichtman AH
    AAPS J; 2009 Jun; 11(2):342-52. PubMed ID: 19430909
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Physical withdrawal in rats tolerant to delta 9-tetrahydrocannabinol precipitated by a cannabinoid receptor antagonist.
    Tsou K; Patrick SL; Walker JM
    Eur J Pharmacol; 1995 Jul; 280(3):R13-5. PubMed ID: 8566091
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Novel behavioral assays of spontaneous and precipitated THC withdrawal in mice.
    Trexler KR; Nass SR; Crowe MS; Gross JD; Jones MS; McKitrick AW; Siderovski DP; Kinsey SG
    Drug Alcohol Depend; 2018 Oct; 191():14-24. PubMed ID: 30071445
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of the cannabinoid ligand SR 141716A alone or in combination with delta9-tetrahydrocannabinol or scopolamine on learning in squirrel monkeys.
    Nakamura-Palacios EM; Winsauer PJ; Moerschbaecher JM
    Behav Pharmacol; 2000 Aug; 11(5):377-86. PubMed ID: 11103889
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Hyperlocomotion and paw tremors are two highly quantifiable signs of SR141716-precipitated withdrawal from delta9-tetrahydrocannabinol in C57BL/6 mice.
    Huang P; Liu-Chen LY; Unterwald EM; Cowan A
    Neurosci Lett; 2009 Nov; 465(1):66-70. PubMed ID: 19733208
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea.
    Parker LA; Mechoulam R; Schlievert C; Abbott L; Fudge ML; Burton P
    Psychopharmacology (Berl); 2003 Mar; 166(2):156-62. PubMed ID: 12528012
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of prevalent phytocannabinoids in the acetic acid model of visceral nociception.
    Booker L; Naidu PS; Razdan RK; Mahadevan A; Lichtman AH
    Drug Alcohol Depend; 2009 Nov; 105(1-2):42-7. PubMed ID: 19679411
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JWH-018 and JWH-073: Δ⁹-tetrahydrocannabinol-like discriminative stimulus effects in monkeys.
    Ginsburg BC; Schulze DR; Hruba L; McMahon LR
    J Pharmacol Exp Ther; 2012 Jan; 340(1):37-45. PubMed ID: 21965552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cannabinoid precipitated withdrawal by the selective cannabinoid receptor antagonist, SR 141716A.
    Aceto MD; Scates SM; Lowe JA; Martin BR
    Eur J Pharmacol; 1995 Aug; 282(1-3):R1-2. PubMed ID: 7498260
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prostaglandin E2 attenuates SR141716A-precipitated withdrawal in tetrahydrocannabinol-dependent mice.
    Anggadiredja K; Yamaguchi T; Tanaka H; Shoyama Y; Watanabe S; Yamamoto T
    Brain Res; 2003 Mar; 966(1):47-53. PubMed ID: 12646307
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CB
    Trexler KR; Eckard ML; Kinsey SG
    Pharmacol Biochem Behav; 2019 Feb; 177():27-33. PubMed ID: 30597181
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Differential disruption of response alternation by precipitated Δ
    Eckard ML; Kinsey SG
    Pharmacol Biochem Behav; 2024 Mar; 236():173718. PubMed ID: 38272272
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SR-141716A-induced stimulation of locomotor activity. A structure-activity relationship study.
    Bass CE; Griffin G; Grier M; Mahadevan A; Razdan RK; Martin BR
    Pharmacol Biochem Behav; 2002 Dec; 74(1):31-40. PubMed ID: 12376150
    [TBL] [Abstract][Full Text] [Related]  

  • 36. SR 141716A differentially attenuates the behavioral effects of delta9-THC in rhesus monkeys.
    McMahon LR; Amin MR; France CP
    Behav Pharmacol; 2005 Sep; 16(5-6):363-72. PubMed ID: 16148440
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Central and peripheral mechanisms contribute to the antiemetic actions of delta-9-tetrahydrocannabinol against 5-hydroxytryptophan-induced emesis.
    Darmani NA; Johnson JC
    Eur J Pharmacol; 2004 Mar; 488(1-3):201-12. PubMed ID: 15044052
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Effects of chronic Delta(9)-tetrahydrocannabinol treatment on hippocampal extracellular acetylcholine concentration and alternation performance in the T-maze.
    Nava F; Carta G; Colombo G; Gessa GL
    Neuropharmacology; 2001 Sep; 41(3):392-9. PubMed ID: 11522331
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interactions between the CB1 receptor agonist Delta 9-THC and the CB1 receptor antagonist SR-141716 in rats: open-field revisited.
    Järbe TU; Andrzejewski ME; DiPatrizio NV
    Pharmacol Biochem Behav; 2002 Nov; 73(4):911-9. PubMed ID: 12213538
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dependence on delta 9-tetrahydrocannabinol: studies on precipitated and abrupt withdrawal.
    Aceto MD; Scates SM; Lowe JA; Martin BR
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1290-5. PubMed ID: 8819514
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.